Bharat Parenterals Limited Q2 FY27 results deck summary

Results deck of 29 Oct 2026, summarised by AI from the filing.

Consolidated Q2 FY27 revenue ₹136.3 cr and PAT ₹11.8 cr, as Innoxel swung to a ₹5.4 cr profit on its first US CMO launch.

Key takeaways

1. Group profit Consolidated PAT was ₹11.8 cr against a ₹(8.6) cr loss in Q2 FY26, on revenue of ₹136.3 cr (+110.9% YoY).
2. Innoxel swing Innoxel turned to a ₹5.4 cr PAT from a ₹(11.0) cr loss in Q2 FY26, with revenue doubling QoQ to ₹44.5 cr while other expenses held flat.
3. US CMO launch The first commercial CMO product was launched in the US by its sponsor on 20-Oct-2026, with EBITDA expected to build through H2 as supply scales.

Original filing on BSE

Bharat Parenterals Limited earnings call, investor presentation and press release summaries

• Q2 FY27: Results deck (29 Oct 2026)
• Q1 FY27: Results deck (5 Aug 2026)
• Q4 FY26: Earnings call (19 May 2026), Results deck (18 May 2026)
• Q3 FY26: Results deck (30 Jan 2026)
• Q2 FY26: Earnings call (12 Nov 2025), Results deck (12 Nov 2025)
• Q1 FY26: Results deck (28 Jul 2025)
• Q4 FY25: Earnings call (14 May 2025)